Ovarian cancer causes more deaths than any other gynecologic malignancy in developed countries. Sixteen million sequence variants, identified through whole-genome sequencing of 457 Icelanders, were imputed to 41,675 Icelanders genotyped using SNP chips, as well as to their relatives. Sequence variants were tested for association with ovarian cancer (N of affected individuals = 656). We discovered a rare (0.41% allelic frequency) frameshift mutation, c.2040_2041insTT, in the BRIP1 (FANCJ) gene that confers an increase in ovarian cancer risk (odds ratio (OR) = 8.13, P = 2.8 × 10 −14 ). The mutation was also associated with increased risk of cancer in general and reduced lifespan by 3.6 years. In a Spanish population, another frameshift mutation in BRIP1, c.1702_1703del, was seen in 2 out of 144 subjects with ovarian cancer and 1 out of 1,780 control subjects (P = 0.016). This allele was also associated with breast cancer (seen in 6/927 cases; P = 0.0079). Ovarian tumors from heterozygous carriers of the Icelandic mutation show loss of the wild-type allele, indicating that BRIP1 behaves like a classical tumor suppressor gene in ovarian cancer.
l e t t e r s phasing information 10 . The nationwide Icelandic genealogical database then allows the propagation of this genotype information and the creation of in silico genotypes for the close relatives of the chipgenotyped individuals (see Online Methods for a detailed description). This approach has recently led to the discovery of two missense mutations that greatly increase the risks of developing sick sinus syndrome 11 and gout 12 , respectively.
To search for sequence variants that associate with invasive ovarian cancer, we performed genome-wide association scans of 15, 957, 390 autosomal SNPs that were identified through whole-genome sequencing of 457 Icelanders and imputed to Icelandic individuals with cancer and control subjects. A total of 68 Icelandic individuals with ovarian cancer had been chip-genotyped with the Illumina HumanHap300 or CNV370 chips, and an additional 572 subjects with ovarian cancer were assigned in silico genotypes. The genotypes of the subjects with cancer were compared to those of control subjects who were matched to them by genotype informativeness (see Supplementary Note), including a total of 41,607 chip-genotyped controls. Excluding markers that are correlated with the known BRCA2 999del5 founder mutation in the Icelandic population 13 , the strongest associations with ovarian cancer were identified for nine highly correlated SNPs on chromosome 17q23.2 (Supplementary Table 1 ). The most significant association was with the C allele of rs34289250 (OR = 7.95, P = 5.65 × 10 −13 , allelic frequency of 0.89% in control subjects). This SNP is localized to an intron of BRIP1 (also known as BACH1 and FANCJ) (Fig. 1) . BRIP1 is located 20 Mb telomeric of the BRCA1 gene and encodes the BRCA1-interacting protein C-terminal helicase 1 protein, which is required for the normal double-strand break repair function of BRCA1 (ref. 14) . Biallelic mutations in BRIP1 result in the chromosome instability disorder Fanconi anemia (FS) complementation group J [15] [16] [17] , and heterozygous inactivating mutations have been reported to have a modest effect on breast cancer risk 14, 18 .
Using whole-genome sequence data from ten carriers of rs34289250, we examined genes in the surrounding region for exonic mutations that might explain the strong association with ovarian cancer. A novel 2-bp insertion in exon 14 of the BRIP1 gene (c.2040_ 2041insTT, accession number NM_032043) was detected in four of the ten SNP carriers but in none of the 447 non-carriers analyzed. The mutation causes a frameshift (p.Leu680fs) and premature termination of protein translation at amino acid 687 out of the 1,249 residues in the full-length protein (Supplementary Fig. 1 ). Using Sanger sequencing and microsatellite genotyping, we directly genotyped the insertion in 11,741 Icelandic subjects with cancer and 3,913 control subjects, including 318 individuals with ovarian cancer. On the basis of these data, the insertion was imputed to both those who had been genotyped using chips and their relatives who had not been genotyped. Combining results from directly genotyped and imputed subjects with cancer, the association between ovarian cancer and the insertion became even more significant (OR = 8.13 (95% confidence interval (CI) 4.74, 13.95), P = 2.8 × 10 −14 ) ( Table 1) .
Mutations in the genes shown to increase risk of ovarian cancer, including BRCA1, BRCA2 and the MMR genes, are also associated with an increased risk of other cancer types, mainly breast and pancreatic cancers in the case of BRCA1 and BRCA2, and colorectal and endometrial cancers in the case of the MMR genes. We determined whether c.2040_2041insTT is associated with an increase in the risk of other cancer types by using cancer diagnoses information from the nationwide Icelandic Cancer Registry and genotype information from individuals with cancer (14,331 directly genotyped or chip-genotyped subjects and 16,873 in silico-genotyped subjects; 23 different cancer types represented) (Supplementary Table 2 ). When all cancers were analyzed together, carriers of the insertion had an increased risk of being diagnosed with cancer in general (OR = 1.50, P = 1.5 × 10 −6 ) ( Table 1 and Supplementary Table 2) . Given the large effect of the insertion on ovarian cancer susceptibility and the fact that ovarian cancer can co-occur with other cancer types, we repeated the analysis and excluded subjects with ovarian cancer (Supplementary Table 3 ). Even with these conditions, the risk of developing any cancer remained significant (OR = 1.36, P = 9.2 × 10 −4 ). Although no cancer type was by itself significantly associated with the insertion after correcting for the number of tests ( Table 1 and Supplementary Table 2) , two cancer types showed nominally significant association: pancreatic cancer (OR = 2.71, P = 0.0069) and rectal cancer (OR = 2.25, P = 0.025). In total, 16 of the 22 cancer types showed an effect in the same direction as ovarian cancer (Supplementary Table 3) . Notably, the insertion does not show significant association with breast cancer in this large sample set (OR = 1.28, P = 0.25).
Carriers of BRCA1 mutations are on average diagnosed with breast and ovarian cancer earlier than non-carriers, and a similar trend holds true for the diagnosis of breast cancer in carriers of BRCA2 mutations 19 . The 656 Icelandic individuals with direct or imputed genotype information who had ovarian cancer were on average 59.8 years of age (s.d. = 15.5 years) at diagnosis, and carriers of the c.2040_2041insTT were 8.5 years older at diagnosis than non-carriers (95% CI 2.7, 14.2; P = 0.0039). The average age at diagnosis of the 131 Spanish individuals with ovarian cancer, according to available data, was 61.5 (s.d. = 13.9), and the two carriers of the c.1702_1703del mutation were diagnosed at ages 68 and 71, an average 8.1 years after the age of diagnosis of non-carriers (P = 0.41).
We examined the lifespan of 8,342 deceased Icelanders who had been directly genotyped or imputed for the c.2040_2041insTT insertion and 7,604 deceased Icelanders with high-quality in silico genotypes who were born after 1900 and lived to be at least 50 years of age. We found that the insertion reduces lifespan in the Icelandic population by 3.6 years (95% CI 1.5, 5.7 years, P = 7.2 × 10 −4 ).
Although the exons of the BRIP1 gene have been extensively sequenced in patients with Fanconi anemia and familial breast cancer, very few frameshift mutations have been found 20 . We did not observe the c.2040_2041insTT insertion in subjects with ovarian 1 1 0 6 VOLUME 43 | NUMBER 11 | NOVEMBER 2011 Nature GeNetics l e t t e r s cancer or in control subjects from The Netherlands (307 affected individuals and 921 control subjects), Spain (144 affected individuals and 896 control subjects) or Finland (55 affected individuals and 1,000 control subjects). To screen for additional mutations in BRIP1 that might contribute to ovarian cancer risk in Icelanders or in other populations, we sequenced the whole gene (exons, introns and the upstream regulatory region) in individuals with ovarian cancer or control subjects from Iceland, The Netherlands and Spain, using a pooling strategy in which samples from ovarian cancer subjects and control subjects were pooled separately, amplified by long-range PCR and sequenced using Solexa technology. Only one deletion was identified in this analysis, c.1702_1703del (NM_032043), which was found only in the pooled sequences of Spanish individuals with cancer. This out-of-frame mutation (p.Asp568fs) is located in exon 12 and leads to a termination of protein translation at amino acid 576 ( Fig. 1 and Supplementary Fig. 1) . Genotyping of the deletion in subjects with cancer and control subjects from Spain showed that the deletion is very rare (allelic frequency 0.03% in control subjects, N = 1,780) but associates with a greatly increased risk of ovarian cancer (OR = 25, P = 0.016) and a significant risk of breast cancer (OR = 12, P = 0.0079) ( Table 2 ). The deletion was only found in one subject with lung cancer out of the 2,758 Spanish individuals with other cancer types that were included in the study (Supplementary Table 4) . No additional genotype information, either locally or genome-wide, was available for Spanish individuals. In addition to the deletion found in the Spanish population, we genotyped 11 coding variants identified through the pool sequencing (10 missense variants and the known Fanconi anemia-associated variant R798X) as well as 3 missense variants that have previously been found in individuals with breast cancer (M299I, Q944E and P1034L) but that were not actually observed in any of the sequenced pools in the three populations studied (Supplementary Table 5 ). In short, these variants were either found at similar frequencies in subjects with cancer and control subjects, or they were too rare to be conclusively associated with ovarian cancer. Three of the four common variants reported to associate with ovarian cancer [7] [8] [9] showed significant association in our data-rs3814113-T at 9p22 (OR = 1.28, P = 0.0037), rs2072590-A at 2q31 (OR = 1.24, P = 0.0089) and rs2363956-T at 19p13 (OR = 1.28, P = 0.0022)-whereas rs10088218-G at 8q24 did not show significant association (OR = 1.11, P = 0.39).
The BRIP1 protein interacts with the BRCT domain of BRCA1 and, either in combination with BRCA1 or independently, acts to preserve the integrity of the genome. BRIP1 is required for homologous recombination-mediated double-strand break repair 15 , the execution of the G2/M cell-cycle checkpoint 21 and for normal progression through S phase by assisting in the resolution of stalled replication forks 22 . Furthermore, mutations in BRIP1 that impair its helicase function render cells highly sensitive to cross-linking agents, such as cisplatin 23 . BRIP1 is located about 20 Mb telomeric to BRCA1, in a region that is frequently lost in ovarian tumors, and previous studies have suggested that a tumor suppressor, distinct from BRCA1, may reside in this region 24 . We tested whether BRIP1 is a classical tumor-suppressor gene, which is characterized by loss of the wild-type allele in the tumors of heterozygous carriers. We obtained ovarian tumor samples from ten carriers of the Icelandic mutation (two fresh-frozen and eight paraffin-embedded) and used PCR and Sanger sequencing of genomic DNA to test for loss of heterozygosity (LOH). Loss of the wild-type allele had occurred in eight of the ten tumors (Supplementary Fig. 2 ). Whole-genome sequencing of tumor DNA from the two freshly frozen tumors further confirmed the LOH at the BRIP1 locus (Supplementary Table 6 ). Finally, we assessed the ratio of wild-type to mutant mRNA by using Sanger sequencing of cDNA. Both tumors showed greatly reduced mRNA expression of the wild-type allele relative to the mutant allele, supporting the idea that the wild-type allele is lost in most cells within the tumor sample (Supplementary Fig. 3 ).
In conclusion, we have discovered frameshift mutations in the BRIP1 gene that greatly affect the risk of invasive ovarian cancer. The Icelandic mutation increases the risk of developing some form of cancer by 36%, after removing all cases of ovarian cancer from the data set. Furthermore, the lives of BRIP1 mutation carriers are on average 3.6 years shorter than those of non-carriers. Ovarian tumors from BRIP1 mutation carriers show loss of the wild-type allele, suggesting that the BRIP1 gene behaves like a classical tumor suppressor gene in ovarian cancer and that tumors with bi-allelic loss of BRIP1 may be good targets for therapeutic agents that affect DNA repair pathways. Because of the relatively low prevalence of ovarian cancer, apparently sporadic cases may actually be caused by rare mutations that have large effects. Deleterious mutations are more likely to reach a frequency that allows for their detection in founder populations like the one in Iceland, rather than in more outbred populations, as demonstrated by the For the individual cancers, directly typed subjects with cancer are compared to 3,913 directly typed control subjects, in each case excluding the individuals that are known to have the cancer from the control group. The remaining subjects with cancer that have been imputed (either chip typed or in silico genotyped) are compared to over 40,000 controls and then combined using the Mantel-Haenszel model (OR with 95% CI and P value given).
a The allele frequency in the imputed cases is estimated from the directly genotyped control subject frequency and the OR for the imputed individuals. Microsatellite genotyping. PCR amplifications were set up and pooled using Zymark SciClone ALH 500 robots. The sequences of the primers used for genotyping are listed (Supplementary Table 8) , and conditions for PCR reactions are described (Supplementary Note). PCR products were supplemented with an internal size standard, and the fragments were separated and detected on an Applied Biosystems model 3730 sequencer using Genescan (v. 3.0) peak-calling software. Alleles were called using an internal allele-calling program 29 .
Association analysis. Results from multiple affected:control subject groups were combined using a Mantel-Haenszel model in which the groups were allowed to have different population frequencies for alleles and genotypes but were assumed to have common ORs. Observed allele frequencies are given for subjects with cancer and control subjects that were directly genotypes. For genotypes that were imputed, the allele frequency is estimated using the equation
based on the frequency in controls that were directly genotyped (θ) and the OR estimate for the imputed individuals.
Isolation of nucleic acids from fresh-frozen and paraffin-embedded tissue samples. DNA was extracted from frozen and paraffin-embedded tissue sections using MasterPure reagents (Epicentre Biotechnologies). For paraffinembedded tissue, paraffin was removed before extraction by heating to 95 °C in tissue and cell lysis solution (TCLS), cooling on ice and transferring the lysate to clean tubes. Reagent volumes were adjusted according to the amount of tissue. Tissue sections were lysed at 22 °C and were rotated until visibly digested. The manufacturer's instructions were followed for the remainder of the protocol. RNA was extracted from frozen tissue sections using RNAzol RT (Molecular Research Centre). Tissue sections were homogenized using a rotor-stator homogenizer. The manufacturer's protocol for the isolation of RNA molecules of >200 bp in length was followed.
Test for BRIP1 expression and LOH in ovarian tumor samples. RNA samples from freshly frozen ovarian tumors were converted to cDNA using the High Capacity cDNA Reverse Transcriptase kit (Applied Biosystems). The region surrounding c.2040_2041insTT was PCR amplified from cDNA from frozen tumors and genomic DNA from frozen and paraffin-embedded tumors using conventional methods. (Primer sequences are listed in Supplementary Table 9 .) PCR fragments were sequenced using the same primers and Big-Dye R terminator v3.1 chemistry and then loaded onto a 3730 DNA Analyzer.
Whole-genome sequencing of tumor DNA. The TruSeq sample preparation kit (Illumina) was used for the preparation of sequencing libraries of genomic DNA from tumor samples and matched blood samples. The method was essentially the same as described above for germline DNA, except that the DNA input was 1 µg and the manufacturer-supplied TruSeq adaptors and PCR primer cocktail were used. Purification of samples following PCR amplification was performed by using AMPure XP beads instead of gel electrophoresis.
